| Intensive glycemic control and the prevention of cardiovascular events: implications of the ACCORD, ADVANCE, and VA diabetes trials: a position statement of the American … JS Skyler, R Bergenstal, RO Bonow, J Buse, P Deedwania, EAM Gale, ... Circulation 119 (2), 351-357, 2009 | 1959 | 2009 |
| Rituximab, B-lymphocyte depletion, and preservation of beta-cell function MD Pescovitz, CJ Greenbaum, H Krause-Steinrauf, DJ Becker, ... New England Journal of Medicine 361 (22), 2143-2152, 2009 | 1127 | 2009 |
| Practical recommendations for the management of diabetes in patients with COVID-19 SR Bornstein, F Rubino, K Khunti, G Mingrone, D Hopkins, AL Birkenfeld, ... The lancet Diabetes & endocrinology 8 (6), 546-550, 2020 | 1062 | 2020 |
| Staging presymptomatic type 1 diabetes: a scientific statement of JDRF, the Endocrine Society, and the American Diabetes Association RA Insel, JL Dunne, MA Atkinson, JL Chiang, D Dabelea, PA Gottlieb, ... Diabetes care 38 (10), 1964-1974, 2015 | 1021 | 2015 |
| Differentiation of diabetes by pathophysiology, natural history, and prognosis JS Skyler, GL Bakris, E Bonifacio, T Darsow, RH Eckel, L Groop, ... Diabetes 66 (2), 241-255, 2017 | 1003 | 2017 |
| An anti-CD3 antibody, teplizumab, in relatives at risk for type 1 diabetes KC Herold, BN Bundy, SA Long, JA Bluestone, LA DiMeglio, MJ Dufort, ... New England Journal of Medicine 381 (7), 603-613, 2019 | 760 | 2019 |
| Effects of oral insulin in relatives of patients with type 1 diabetes: The Diabetes Prevention Trial-Type 1 JS Skyler, JP Krischer, J Wolfsdorf, C Cowie Diabetes care 28 (5), 1068, 2005 | 750 | 2005 |
| C-peptide is the appropriate outcome measure for type 1 diabetes clinical trials to preserve β-cell function: report of an ADA workshop, 21–22 October 2001 JP Palmer, GA Fleming, CJ Greenbaum, KC Herold, LD Jansa, H Kolb, ... Diabetes 53 (1), 250-264, 2004 | 620 | 2004 |
| Co-stimulation modulation with abatacept in patients with recent-onset type 1 diabetes: a randomised, double-blind, placebo-controlled trial T Orban, B Bundy, DJ Becker, LA DiMeglio, SE Gitelman, R Goland, ... The Lancet 378 (9789), 412-419, 2011 | 599 | 2011 |
| Validation of the insulin sensitivity index (ISI0, 120): comparison with other measures M Gutt, CL Davis, SB Spitzer, MM Llabre, M Kumar, EM Czarnecki, ... Diabetes research and clinical practice 47 (3), 177-184, 2000 | 590 | 2000 |
| The management of type 1 diabetes in adults. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) RIG Holt, JH DeVries, A Hess-Fischl, IB Hirsch, MS Kirkman, T Klupa, ... Diabetes care 44 (11), 2589-2625, 2021 | 559 | 2021 |
| Insulin action during pregnancy: studies with the euglycemic clamp technique EA Ryan, MJ O'Sullivan, JS Skyler Diabetes 34 (4), 380-389, 1985 | 556 | 1985 |
| The economic burden of diabetes and the benefits of improved glycemic control: The potential role of a continuous glucose monitoring system JS Skyler Diabetes Technology & Therapeutics 2 (1, Supplement 1), 7-12, 2000 | 489 | 2000 |
| Cardiovascular outcomes trials in type 2 diabetes: where do we go from here? Reflections from a diabetes care editors’ expert forum WT Cefalu, S Kaul, HC Gerstein, RR Holman, B Zinman, JS Skyler, ... Diabetes care 41 (1), 14-31, 2018 | 416 | 2018 |
| Efficacy of inhaled human insulin in type 1 diabetes mellitus: a randomised proof-of-concept study JS Skyler, WT Cefalu, IA Kourides, WH Landschulz, CC Balagtas, ... The Lancet 357 (9253), 331-335, 2001 | 412 | 2001 |
| Antigen-based therapy with glutamic acid decarboxylase (GAD) vaccine in patients with recent-onset type 1 diabetes: a randomised double-blind trial DK Wherrett, B Bundy, DJ Becker, LA DiMeglio, SE Gitelman, R Goland, ... The Lancet 378 (9788), 319-327, 2011 | 400 | 2011 |
| Interleukin-1 antagonism in type 1 diabetes of recent onset: two multicentre, randomised, double-blind, placebo-controlled trials A Moran, B Bundy, DJ Becker, LA DiMeglio, SE Gitelman, R Goland, ... The Lancet 381 (9881), 1905-1915, 2013 | 351 | 2013 |
| Diabetes mellitus: pathogenesis and treatment strategies JS Skyler Journal of medicinal chemistry 47 (17), 4113-4117, 2004 | 330 | 2004 |
| Fall in C-peptide during first 2 years from diagnosis: evidence of at least two distinct phases from composite Type 1 Diabetes TrialNet data CJ Greenbaum, CA Beam, D Boulware, SE Gitelman, PA Gottlieb, ... Diabetes 61 (8), 2066-2073, 2012 | 320 | 2012 |
| Intensive insulin therapy for treatment of type I diabetes IB Hirsch, R Farkas-Hirsch, JS Skyler Diabetes Care 13 (12), 1265-1283, 1990 | 319 | 1990 |
